New alpha therapy targets tough prostate cancer
NCT ID NCT07214961
First seen Nov 01, 2025 · Last updated May 02, 2026 · Updated 29 times
Summary
This early-stage study tests a new drug called AB001, which delivers a powerful radioactive particle directly to prostate cancer cells. It is for men with advanced prostate cancer that no longer responds to hormone therapy. The goal is to find the safest and most effective dose and schedule.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BAMF Health
Grand Rapids, Michigan, 49503, United States
-
United Theranostics
Princeton, New Jersey, 08540, United States
-
XCancer
Omaha, Nebraska, 68130, United States
Conditions
Explore the condition pages connected to this study.